Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid-refractory or Dependent Chronic GVHD — CARE  

Chronic GVHD After HCT for Cancer or Immune Disease Clinical Trial

Official title: Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid-refractory or Dependent Chronic GVHD

Status Active, not recruiting

Clinical Trial Summary

Phase II multicenter, Canadian only study - open to 25 subjects. Study open to subjects with steroid-refractory or dependent chronic graft vs host disease.

Series of 6 aphereses and 28 re-infusions over 24 weeks. Primary endpoint is FFS at 24 weeks. Primary objective is to measure the efficacy of CARE (Continuous Alloreactive T-Cell depletion and Regulatory T-cell Expansion)

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Chronic GVHD After HCT for Cancer or Immune Disease
• Immune System Diseases

• NCT number: NCT02519816
• Study type: Interventional
• Source: Maisonneuve-Rosemont Hospital
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: March 2016
• Completion date: January 1, 2020